Instil Bio Q1 net loss $4.32/share; restructuring charges $16.1M; cash $111.8M

Instil Bio, Inc.

2025-Q1 EPS reported -$4.32

Net loss per share $4.32 (GAAP) vs $3.74 YoY; non-GAAP $1.32 vs $2.39.
Cash and investments $111.8M, down from $115.1M at Dec 31, 2024; runway beyond 2026.
Restructuring & impairment charges $16.1M vs $4.3M YoY; R&D $5.4M, G&A $9.1M.
AXN-2510/IMM2510 China trial ongoing; initial 1L NSCLC data expected 2H 2025.
U.S. clinical study of AXN-2510/IMM2510 in 1L NSCLC anticipated before end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.